• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

I'm Giving Dynavax Another Shot -- a Booster Shot

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.
By BRET JENSEN
May 08, 2022 | 07:31 AM EDT
Stocks quotes in this article: DVAX

I outlined a covered-call strategy in November on Dynavax Technologies (DVAX) . But, unfortunately, that was before the bottom dropped out of the market. Thanks partly to algorithmic trading, there are several hundred small biotech names selling at or under cash value on their balance sheets.

I "rolled" my original April options on that play.

I am now doubling down on that holding, and adding exposure to the name. Dynavax reported first-quarter results last Thursday. The stock managed a decent gain Friday, even as the company had a revenue miss. This was because of lumpy sales from its adjuvant used by several Covid vaccines. The company confirmed forward guidance calling for $550 million of revenue in fiscal 2022 with a 50% gross margin. Given it has signed contracts for its CpG 1018 adjuvants in 2022, the guidance seems more than solid. The company also had unadjusted earnings per share of 26 cents, two pennies above the consensus.

Analysts have $1.20 a share in profit penciled in for fiscal 2022. Now revenues will likely fall off significantly for the company's Covid adjuvants in next fiscal year, as the pandemic eventually ebbs. The company has used this burst in revenue to build a net cash hoard of approximately $280 million, which it will add to this fiscal year. The stock's market cap is around $1.2 billion.

In addition, the company is rapidly taking market share with its hepatitis B vaccine, which is "best of breed." Heplisav-B did $20.8 million worth of sales in the first quarter, compared to just $8.3 million in the same quarter a year ago. The Center for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recently recommended hepatitis B vaccination for all adults aged 19 to 59. Management believes this will help bump the annual market for hepatitis B vaccines to $800 million just in the United States by 2027. It is a market DVAX plans to dominate.

Heplisav-B offers protection via two doses over one month rather than three doses over six months, compared to Entergis-B, which has been the standard for a generation. It also is more effective (95% vs. 81%) in providing this protection. Finally, the company has some early-stage vaccine candidates in development including for the one-shot for tetanus, diphtheria and pertussis, and for shingles, in development. Study readouts for these efforts should be disclosed this year. Finally, H.C. Wainwright reiterated a "Buy" rating and $28 price target on DVAX after the earnings release on Thursday. I expect other analyst firms to follow suit next week.

Your Option (Strategy)

Here is how I added to my position in DVAX via a covered call order.

Using the January $10 call strikes, fashion a covered call order with a net debit in the $7.10 to $7.30 a share range (net stock price -- option premium). This strategy provides over 20% of downside protection and nearly 40% potential upside even if the stock does nothing over the option duration.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long DVAX.

TAGS: Investing | Options | Stocks | Healthcare | Pharmaceuticals | Health

More from Stocks

Market's Narrow and Dull but Not Bad

James "Rev Shark" DePorre
Mar 29, 2023 4:26 PM EDT

Here are the two things that stood out in Wednesday's trading.

Battery Maker Enovix Could Soon Be Charged Up to Rally Further

Bruce Kamich
Mar 29, 2023 2:56 PM EDT

The stock has been impressive but gains from here may be harder to achieve.

Except for Energy, I'd Be Wary of Cyclical Stocks

Bret Jensen
Mar 29, 2023 11:30 AM EDT

Another increasing concern for equities is that we are likely to see an 'earnings recession'.

Think the Market Action Is Dull Now? Just Wait for the Storm

James "Rev Shark" DePorre
Mar 29, 2023 11:15 AM EDT

Until we have a better feel for what the Fed will do, it will be hard for the market to discount what lies ahead.

Micron Stock Shows Resilience After an 'Ugly' Quarter, But Is It a Buy?

Stephen Guilfoyle
Mar 29, 2023 10:20 AM EDT

This is a tough stock or sector (memory) of the industry to love right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:00 PM EDT CHRIS VERSACE

    AAP Podcast: This Solar Company Is a Head-Turner

    Listen to my interview with Brian Roth, CEO of sol...
  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login